Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹452 Cr revenue.
COGS 73.1%, employees 4.9%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 20.8%▲ | 10.5% |
| ROCE | 38.8%▲ | 13.8% |
| Net Margin | 5.5%▼ | 8.7% |
| EBITDA Margin | 14.0%▼ | 16.0% |
| Debt To Equity | 1.09x▲ | 0.21x |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 |
|---|---|---|
| Revenue | ₹588 Cr +30.3% | ₹452 Cr |
| Other Income | ₹5 Cr +12.3% | ₹5 Cr |
| Total Income | ₹593 Cr +30.1% | ₹456 Cr |
| COGS | ₹425 Cr +28.7% | ₹330 Cr |
| ₹550 Cr +28.4% | ₹429 Cr | |
| Profit Before Tax | ₹43 Cr +56.4% | ₹27 Cr |
| ₹10 Cr +33.3% | ₹8 Cr | |
| Net Profit | ₹33 Cr +65.6% | ₹20 Cr |
| Profit (Owners) | ₹33 Cr +65.6% | ₹20 Cr |
| Minority Interest | ₹0.00 Cr -100.0% | ₹0.00 Cr |
| Other Comprehensive Income | (₹0.34 Cr) 0.0% | (₹0.34 Cr) |
| EPS | ₹64.15 | ₹41.80 |
| Diluted Shares | ₹0.54 Cr | ₹0.47 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Newspaper Clipping- Information regarding 39th Annual General Meeting to be held on 30th June, 2026 through video conference/other audio visual means.
Notice convening 39th Annual General Meeting ("AGM") of Fredun Pharmaceuticals Limited
Annual Report of Fredun Pharmaceuticals Limited for the Financial Year 2025-2026 including the Notice of the 39th Annual General Meeting of the Company scheduled to be held on Tuesday, .... Annual Rep...
Revised intimation of Earnings Conference Call for the quarter Q4 of FY26.
Intimation of Earning Conference call for the quarter Q4 of FY 2026.
Annual Secretarial Compliance Report for the year ended 31st March, 2026.
Newspaper Publication of the Audited Financial Results of the Company for the Quarter and Year ended 31st March, 2026.
Audited Results for the quarter and year ended on 31st March, 2026.
Outcome of Board Meeting held on 25th May, 2026
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve 1. Consider and approve .... Fredun...
Please find enclosed press release titled "Fredun Pharmaceuticals Expands Manufacturing Base with Fifty Facility at Palghar" issued by Fredun Pharmaceuticals Limited.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</...
Intimation of Schedule of ''Bharat Connect Conference'', under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.
Press Release titled Infomerics Upgrade Fredun Pharmaceuticals Credit Rating to BBB+, Boosts Financial Profile.
Press Release tiltled Infomerics Upgrade Fredun Pharmaceuticals Credit Rating to BBB+, Boosts Financial Profile.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.